Navigation Links
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
Date:12/17/2008

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p<0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen

Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001).

Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001)

There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worsening of pre-existing hypertension. Both doses of naproxcinod (375 and 750 mg bid) were similar to placebo, as indicated by one-sided 95% confidence intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001).

Garret FitzGerald, MD, Professor of Medicine and Pharmacology at the University of Pennsylvania School of Medicine, commented:
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1379

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
2. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
3. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
4. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
5. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
6. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
11. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Fla., Nov. 8, 2011 VR Laboratories LLC ... as chief scientific advisor.  Rothman will head scientific ... manufacture and bring to market world-class botanical consumer, ... foreign and domestic markets. In addition to assisting ...
... SPRING, Md., Nov. 8, 2011 The U.S. Food and Drug ... and caregivers on the safe disposal of needles and other ... while traveling. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... created by improperly disposing of used sharps and how users ...
Cached Medicine Technology:James Rothman Named Chief Scientific Advisor at VR Laboratories 2James Rothman Named Chief Scientific Advisor at VR Laboratories 3James Rothman Named Chief Scientific Advisor at VR Laboratories 4FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 2FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 3FDA Launches Website on Safe Disposal of Used Needles and Other "Sharps" 4
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/19/2014)... October 20, 2014 Hastings and Hastings, ... years of service throughout the greater Phoenix area and ... representation with regard to catastrophic automobile accidents. Statistics have ... country and throughout Arizona. As such, Hastings and Hastings ... legal representation for those who have been injured through ...
(Date:10/19/2014)... working in the garment industry for decades, LunaDress’ dress specialists ... one of the company’s top designers, many ladies like prom ... add beauty to them. Chiffon floor length outfits are also ... selection of 2014 long prom dresses. , As a ... in over 20 popular designs. The company intends to meet ...
(Date:10/19/2014)... 2014 Stephen T. Greenberg, M.D., with offices ... the 10th consecutive year as one of Long Island’s best ... also been nominated as the best provider for Botox injections. ... best Day Spa and best Laser Treatment center on Long ... readers can vote for the contest once per day, per ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... Financial Flexibility for their Purchase of Niobe(R) Magnetic Robotic ... 12 Stereotaxis, Inc. (Nasdaq: STXS ) ... Relational Technology Solutions (RTS) that will allow the Company ... for their purchase of Stereotaxis Niobe(R) magnetic robotic systems. ...
... Inc.,(NYSE: WX ), a leading pharmaceutical, biotechnology ... and the United States, today,announced that it will release ... 2009 Shanghai time, and after the US market close ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) , ...
... Conference on Customer and Information Technology Support will be held in Las ... how organizations can communicate with their non-English speaking customers in 150 languages. ... ... service, support and help desk professionals from across the world will gather ...
... Alonso LLP is offering free consultations to Florida homeowners, associations ... defective Chinese drywall. , ... (PRWEB) ... free consultations to Florida homeowners, associations and condominium associations in ...
... and strong throughout MinnesotaMINNEAPOLIS, March 12 A ... that an overwhelming majority (72 percent) of Minnesotans ... respondents said the primary reason for their support ... quit and prevent kids from becoming smokers, and ...
... HAYWARD, Calif., March 11 Solta Medical, Inc. (Nasdaq: ... market, today announced that Silicon Valley Bank, a member company ... provided the company with a $9 million credit facility. ... strengthens our ability to pursue our strategic initiatives in the ...
Cached Medicine News:Health News:Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers 2Health News:Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers 3Health News:WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009 2Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 2Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 3Health News:Defective Chinese Drywall Lawsuit: Florida Homeowners' Associations and Condominium Associations Plagued by Defective Chinese Drywall Urged to Investigate their Rights 2Health News:Defective Chinese Drywall Lawsuit: Florida Homeowners' Associations and Condominium Associations Plagued by Defective Chinese Drywall Urged to Investigate their Rights 3Health News:New Poll: 72 Percent of Minnesotans Support Tobacco Tax Increase 2Health News:New Poll: 72 Percent of Minnesotans Support Tobacco Tax Increase 3Health News:Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: